ORLANDO, FL - Nutriband Inc. (NASDAQ:NTRB), a developer of transdermal pharmaceutical products, has announced a licensing agreement to incorporate Bitrex® brand denatonium benzoate into its AVERSA™ Fentanyl patch, a product designed to deter abuse. The agreement, revealed on September 20, 2024, aims to improve safety by preventing misuse and accidental exposure to the potent opioid fentanyl.
The AVERSA™ technology uses a proprietary aversive agent coating that employs taste aversion, making the patches extremely bitter and less likely to be orally abused or accidentally ingested, especially by children. The FDA has cited accidental exposure to fentanyl patches as a significant cause of poisoning in children, leading to severe illness or death.
Bitrex® is recognized as the most bitter substance in the world and has been safely used in various household and industrial products to prevent accidental poisonings. Nutriband's partnership with Kindeva Drug Delivery, a global contract development and manufacturing organization, intends to integrate this abuse-deterrent technology into commercial scale manufacturing of FDA-approved transdermal fentanyl patches.
The AVERSA Fentanyl patch is poised to be the first of its kind, potentially reaching annual peak sales in the U.S. of $80 million to $200 million, according to a market analysis report by Health Advances in 2022.
Nutriband's portfolio includes a broad intellectual property coverage for its AVERSA™ technology, with patents granted in multiple jurisdictions, including the United States, Europe, and Asia. The company's focus on preventing drug abuse and misuse is part of a larger effort to ensure the safe use of powerful medications like fentanyl while maintaining their availability for patients in need.
This initiative represents a step forward in addressing the opioid crisis by introducing preventative measures directly into the delivery system of pain-relieving drugs. The collaboration with Kindeva Drug Delivery will be crucial in bringing this innovative solution to market, aiming to safeguard patients and communities from the risks associated with opioid medications.
The information in this article is based on a press release statement from Nutriband Inc.
In other recent news, Nutriband Inc. has announced a share repurchase program, planning to buy back up to $1,000,000 of its common stock. The company is also making significant strides with its AVERSA Fentanyl patch, a product designed to combat drug abuse and misuse. Nutriband is nearing a trademark acquisition for the AVERSA technology and is advancing the commercial-scale manufacturing process for AVERSA Fentanyl in collaboration with Kindeva Drug Delivery.
The company has recently appointed Sergei Glinka to its board of directors, following his $4.5 million investment, which is expected to support the FDA approval process for the AVERSA technology. Nutriband has also secured $8.4 million in a private placement funding round to advance AVERSA Fentanyl.
Market analysis by Health Advances suggests that AVERSA Fentanyl could achieve peak annual sales between $80 million and $200 million in the U.S. market. These recent developments highlight Nutriband's ongoing efforts to bring innovative pharmaceutical solutions to the market.
InvestingPro Insights
Nutriband Inc. (NASDAQ:NTRB) has made strides in enhancing the safety of opioid medications with its AVERSA™ Fentanyl patch, and the financial metrics reflect a dynamic picture of the company. With a market capitalization of $62.14 million, Nutriband's financial health is underscored by its ability to hold more cash than debt, as highlighted in one of the InvestingPro Tips. This is a vital indicator of the company's financial stability and its capacity to invest in new technologies and market expansions.
Investors should note that while Nutriband is not currently profitable, with a negative P/E ratio of -7.02 and an adjusted P/E ratio for the last twelve months as of Q2 2025 at -8.74, analysts are anticipating sales growth in the current year. This anticipated growth could be a sign of the company's potential to capitalize on its innovative products and technologies. In addition, Nutriband's liquid assets exceed its short-term obligations, providing the company with a cushion to navigate market conditions and invest in growth opportunities.
The company's stock has experienced significant volatility, with a substantial return over the last six months of 107.35% and an impressive year-to-date price total return of 118.97%. This performance reflects investor optimism, possibly driven by the company's innovative approach to addressing the opioid crisis and its recent licensing agreement. However, the revenue growth has seen a downturn, with a decrease of -20.83% over the last twelve months as of Q2 2025, signaling challenges in scaling up sales.
For those looking to delve deeper into Nutriband's financials and future prospects, there are additional InvestingPro Tips available on the InvestingPro platform. In total, there are nine InvestingPro Tips that provide a comprehensive analysis of the company's financial health and market performance. Interested readers can find these tips by visiting the InvestingPro page for Nutriband at https://www.investing.com/pro/NTRB.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.